Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-24T05:35:03.627Z Has data issue: false hasContentIssue false

Chapter 13 - Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD)

from Part 2 - Psychopharmacology of the Main Psychotropic Drug Groups

Published online by Cambridge University Press:  29 May 2020

By
Ulrich Müller-Sedgwick  and
Jane A. Sedgwick-Müller
Edited by
Peter M. Haddad  and
David J. Nutt
Peter M. Haddad
Affiliation:
Hamad Medical Corporation, Qatar
David J. Nutt
Affiliation:
Centre for Neuropsychopharmacology, Division of Psychiatry, Department of Brain Sciences, Imperial College London
Get access

Summary

The aim of this chapter is to enable psychiatrists and nurses to safely prescribe medication for treating attention deficit hyperactivity disorder (ADHD) so that patients across the lifespan get optimal benefits from these medications. In the chapter, we summarize the evidence base for the pharmacological treatment of ADHD and relevant guideline recommendations for prescribing ADHD medications in the UK.

Type
Chapter
Information
Seminars in Clinical Psychopharmacology , pp. 392 - 432
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adler, L, Wilen, T, Zhang, S, et al. (2009). Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence. Am J Addict, 18(5), 393–401.Google Scholar
Advokat, C (2010). What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neurosci Biobehav Rev, 34(8), 1255–1266.CrossRefGoogle ScholarPubMed
Advokat, C, Lane, SM, Luo, C (2011). College students with and without ADHD: comparison of self-report of medication usage, study habits, and academic achievement. J Atten Disord, 15, 656–666.Google Scholar
Ameis, SH, Szatmari, P (2012). Imaging-genetics in autism spectrum disorder: advances, translational impact and future directions. Front Psychiatry, 3(46), 1–13.CrossRefGoogle ScholarPubMed
Ameis, SH, Kassee, C, Corbett-Dick, P, et al. (2018). Systematic review and guide to management of core and psychiatric symptoms in youth with autism. Acta Psychiatr Scand, 138, 379–400.Google Scholar
American Psychiatric Association (APA) (1980). Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. Arlington, VA: American Psychiatric Association.Google Scholar
American Psychiatric Association (APA) (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association.Google Scholar
Andrew, BN, Guan, NC, Jaafar, NRN (2018). The use of methylphenidate for physical and psychological symptoms in cancer patients: a review. Curr Drug Targets, 19(8), 877–887.CrossRefGoogle ScholarPubMed
Asherson, P, Young, AH, Eich-Höchli, D, et al. (2014). Differential diagnosis, comorbidity and treatment of attention-deficit/hyperactivity disorder in relation to bipolar disorder or borderline personality disorder in adults. Curr Med Res Opin, 30(8), 1657–1672.Google Scholar
Biederman, J, Lindsten, A, Sluth, LB, et al. (2019). Vortioxetine for attention deficit hyperactivity disorder in adults: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Psychopharmacol, 33(4), 511–521.Google Scholar
Bijlenga, D, Kulcu, S, van Gellecum, T, Eryigit, Z, Kooij, JJS (2017). Persistence and adherence to psychostimulants, and psychological well-being up to 3 years after specialized treatment of adult attention-deficit/hyperactivity disorder: a naturalistic follow-up study. J Clin Psychopharmacol, 37(6), 689–696.Google Scholar
Boilson, M, Shah, P and Royal College of Psychiatrists in Scotland special interest group in ADHD (2017). ADHD in Adults: Good Practice Guidelines, London: The Royal College of Psychiatrists.Google Scholar
Bolea-Alamanac, BM, Green, A, Verma, G, Maxwell, P, Davies, SJC (2013). Methylphenidate use in pregnancy and lactation: a systematic review of evidence. Br J Clin Pharmacol, 77(1), 96–101.Google Scholar
Bolea-Alamañac, B, Nutt, DJ, Adamou, M, et al. (2014). Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 28(3), 179–203.Google Scholar
Bonell, CP, Hickson, FC, Weatherburn, P, Reid, DS (2010). Methamphetamine use among gay men across the UK. Int J Drug Policy, 21(3), 244–246.CrossRefGoogle ScholarPubMed
Bourne, A, Reid, D, Hickson, F, Torres-Rueda, S, Weatherburn, P (2015). Illicit drug use in sexual settings (‘chemsex’) and HIV/STI transmission risk behaviour among gay men in south London: findings from a qualitative study. Sex Transm Infect, 91(8), 564–568.Google Scholar
Brook, DW, Brook, JS, Zhang, C, Koppel, J (2010). Association between attention-deficit/hyperactivity disorder in adolescence and substance use disorders in adulthood. Arch Pediatr Adolesc Med, 164(10), 930–934.Google Scholar
Butterfield, ME, Saal, J, Young, B, Young, JL (2016). Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: a double blind, placebo-controlled study. Psychiatry Res, 236, 136–141.Google Scholar
Caisley, H, Müller, U (2012). Adherence to medication in adults with attention deficit hyperactivity disorder and pro re nata dosing of psychostimulants: a systematic review. Eur Psychiatry, 27, 343–349.Google Scholar
Canadian ADHD Resource Alliance (CADDRA) (2018). Canadian ADHD Practice Guidelines, 4th ed. Toronto: CADDRA. Available at: www.caddra.ca/canadian-adhd-practice-guidelines (last accessed 15.8.18).Google Scholar
Castaldi, S, Gelatti, U, Orizio, G, et al. (2012). Use of cognitive enhancement medication among Northern Italian university students. J Addict Med, 6, 112–117.Google Scholar
Caye, A, Swanson, JM, Coghill, D, Rohde, LA (2019). Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry, 24, 390–408.Google Scholar
Cederström, C (2016). Like it or not ‘smart drugs’ are coming to the office. Harvard Business Review. Available at: https://hbr.org/2016/05/like-it-or-not-smart-drugs-are-coming-to-the-office (last accessed 1.11.18).Google Scholar
Centers for Disease Control and Prevention (CDC) (2007). Methamphetamine Use and Risk for HIV/AIDS. Available at: file:///C:/Users/K1517101/Downloads/cdc_11778_DS1.pdf (last accessed 1.8.18).Google Scholar
Chan, E, Fogler, JM, Hammerness, PG (2016). Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. JAMA, 315, 1997–2008.CrossRefGoogle ScholarPubMed
Chang, Z, Lichtenstein, P, D’Onofrio, BM, Sjölander, A, Larsson, H (2014). Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry, 71, 319–325.Google Scholar
Chang, Z, D’Onofrio, BM, Quinn, PD, Lichtenstein, P, Larsson, H (2016). Medication for attention-deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study. Biol Psychiatry, 80, 916–922.Google Scholar
Chang, Z, Ghirardi, L, Quinn, PD, et al. (2019). Risks and benefits of ADHD medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol Psychiatry [Epub ahead of print] doi:doi.org/10.1016/j.biopsych.2019.04.009.Google Scholar
Chavez, C, Hollaus, M, Scarr, E, et al. (2010). The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res, 1321, 51–59.CrossRefGoogle Scholar
Chen, Q, Hartman, CA, Haavik, J, et al. (2018). Common psychiatric and metabolic comorbidity of adult attention-deficit/hyperactivity disorder: a population-based cross-sectional study PLoS One, 13(9), e0204516.Google Scholar
Coghill, D, Chen, W, Silva, D (2019). Organizing and delivering treatment for ADHD. In Rohde, LA, Buitelaar, JK, Gerlach, M, Faraone, SV, eds., The World Federation of ADHD Guide, pp. 93–109. [open access pdf and e-book: http://cpo-media.net/ADHD/2019/ebook/HTML/93/].Google Scholar
Cooper, RE, Williams, E, Seegobin, S, et al. (2017). Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial. Eur Neuropsychopharmacol, 27, 795–808.Google Scholar
Cope, LC, Abuzour, AS, Tully, MP (2016). Nonmedical prescribing: where are we now? Ther Adv Drug Saf, 7(4), 165–172.Google Scholar
Cortese, S (2018). Are the effects of methylphenidate uncertain? Ir J Psychol Med, 35, 163–167.Google Scholar
Cortese, S, Tessari, L (2017). Attention-deficit/hyperactivity disorder (ADHD) and obesity: update 2016. Curr Psychiatry Rep, 19(1), 4.Google Scholar
Cortese, S, Brown, TE, Corkum, P, et al. (2013). Assessment and management of sleep problems in youths with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 52, 784–796.Google Scholar
Cortese, S, D’Acunto, G, Konofal, E, Masi, G, Vitiello, B (2017). New formulations of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: pharmacokinetics, efficacy, and tolerability. CNS Drugs, 31, 149–160.Google Scholar
Cortese, S, Adamo, N, Del Giovane, C, et al. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry, 5, 727–738.Google Scholar
Coulter, A, Collins, A (2011). Making shared decision-making a reality: no decision about me, without me. London: The King’s Fund.Google Scholar
Crunelle, CL, van den Brink, W, Moggi, F, et al.; ICASA consensus group, Matthys, F (2018). International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder. Eur Addict Res, 24(1), 43–51.Google Scholar
Cunill, R, Castells, X, Tobias, A, Capellà, D (2015). Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. J Psychopharmacol, 29, 15–23.Google Scholar
Dalley, JW, Roiser, JP (2012). Dopamine, serotonin and impulsivity. Neuroscience, 215, 42–58.Google Scholar
De Crescenzo, F, Cortese, S, Adamo, N, Janiri, L (2017). Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review. Evid Based Ment Health, 20, 4–11.Google Scholar
DeSaints, AD, Webb, EM, Noar, SM (2008). Illicit use of prescription ADHD medications on a college campus: a multimethodological approach. J Am Coll Health, 75, 315–324.Google Scholar
Diav-Citrin, O, Shechtman, S, Arnon, J, et al. (2016). Methylphenidate in pregnancy: a multicentre, prospective, comparative, observational study. J Clin Psychiatry, 77(9), 1176–1181.CrossRefGoogle Scholar
Díaz-Román, A, Mitchell, R, Cortese, S (2018). Sleep in adults with ADHD: systematic review and meta-analysis of subjective and objective studies. Neurosci Biobehav Rev, 89, 61–71.Google Scholar
Dietz, P, Soyka, M, Franke, AG (2016). Pharmacological neuroenhancement in the field of economics: poll results from an online survey. Front Psychol, 7(520), 1–8.Google Scholar
Driver & Vehicle Licensing Agency (DVLA) (2019). Assessing fitness to drive: a guide for medical professionals. Available at: www.gov.uk/government/publications/ assessing-fitness-to-drive-a-guide-for-medical-professionals (last accessed 1.04.19).Google Scholar
DuPaul, GJ, Weyandt, LL, Rossi, JS, et al. (2012). Double-bind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD. J Atten Disord, 16, 202–220.Google Scholar
Eakle, R, Mbogua, J, Mutanha, N, Ress, H (2018). Exploring acceptability of oral PrEP prior to implementation among female sex workers in South Africa. J Int AIDS Soc, 21, e25081.Google Scholar
Edvinsson, D, Ekselius, L (2018a). Long-term tolerability and safety of pharmacological treatment of adult attention-deficit/hyperactivity disorder: a 6-year prospective naturalistic study. J Clin Psychopharmacol, 38(4), 370–375.Google Scholar
Edvinsson, D, Ekselius, L (2018b). Six-year outcome in subjects diagnosed with attention-deficit/hyperactivity disorder as adults. Eur Arch Psychiatry Clin Neurosci, 268(4), 337–347.Google Scholar
Faraone, SV (2018). The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev, 87, 255–270.Google Scholar
Findling, RL, Adler, LA, Spencer, TJ, et al. (2019). Dasotraline in children with attention-deficit/hyperactivity disorder: a six-week, placebo-controlled, fixed-dose trial. J Child Adolesc Psychopharmacol, 29(2), 80–89.Google Scholar
Fredriksen, M, Dahl, AA, Martinsen, EW, et al. (2014). Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity. Eur Neuropsychopharmacol, 24, 1873–1884.Google Scholar
Galbraith, N (2015). The methamphetamine problem. BJPsych Bull, 39, 218–220.Google Scholar
Gillberg, C, Gillberg, IC, Rasmussen, P, et al. (2004). Co-existing disorders in ADHD: implications for diagnosis and intervention. Eur Child Adolesc Psychiatry, 13(Suppl 1), 80–92.Google Scholar
Gillies, GE, McArthur, S (2010). Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol Rev, 62(2), 155–198.Google Scholar
Ginsberg, Y, Lindefors, N (2012). Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension. Br J Psychiatry, 200(1), 68–73.Google Scholar
Golubchik, P, Sever, J, Zalsman, G, Weizman, A (2008). Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. Int Clin Psychopharmacol, 23(4), 228–231.Google Scholar
Gonzales, R, Mooney, L, Rawson, RA (2010). The methamphetamine problem in the United States. Annu Rev Public Health, 31, 385–398.Google Scholar
Gould, ON, Doucette, C (2018). Self-management of adherence to prescribed stimulants in college students with ADD/ADHD. J Atten Disord, 22, 349–355.CrossRefGoogle ScholarPubMed
Graham, J, Coghill, D (2008). Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs, 22(3), 213–237.Google Scholar
Graham, J, Banaschewski, T, Buitelaar, J, et al. (2011). European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry, 20(1), 17–37.Google Scholar
Greely, H, Sanakian, B, Harris, J, et al. (2008). Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456, 702–705.Google Scholar
Halkitis, PN (2010). Reframing HIV prevention for gay men in the United States. Am Psychol, 65(8), 752–763.CrossRefGoogle ScholarPubMed
Halkitis, PN, Levy, MD, Solomon, TM (2016). Temporal relations between methamphetamine use and HIV seroconversion in gay, bisexual, and other men who have sex with men. J Health Psychol, 21(1), 93–99.Google Scholar
Halperin, JM, Marks, DJ (2019). Practitioner review: assessment and treatment of preschool children with attention-deficit/hyperactivity disorder. J Child Psychol Psychiatry [Epub ahead of print] doi:10.1111/jcpp.13014.Google Scholar
Harrison, AG, Edwards, MJ, Parker, KCH (2007). Identifying students faking ADHD: preliminary findings and strategies for detection. Arch Clin Neuropsychol, 22, 577–588.Google Scholar
Heal, DJ, Smith, S, Gosden, J, Nutt, DJ (2013). Amfetamine, past and present: a pharmacological and clinical perspective. J Psychopharmacol, 27, 1–18.Google Scholar
Holloway, K, Bennett, T (2012). Prescription drug misuse among university staff and students: a survey of motives, nature and extent. Drug Educ Prev Polic, 19, 137–144.Google Scholar
Hooberman, D, Stein, TA (1984). Treatment of attention deficit and borderline personality disorders with psychostimulants: case report. J Clin Psychiatry, 45, 441–442.Google Scholar
Hornig-Rohan, M, Amsterdam, JD (2002). Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression. Prog Neuropsychopharmacol Biol Psychiatry, 26(3), 585–589.Google Scholar
Humphreys, KL, Eng, T, Lee, SS (2013). Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry, 70, 740–749.Google Scholar
Husain, M, Mehta, MA (2011). Cognitive enhancement by drugs in health and disease. Trends Cogn Sci, 15(1), 28–36.Google Scholar
Huss, M, McBurnett, K, Cutler, AJ, et al. (2019). Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol, 29, 432–443.Google Scholar
Iaccarino, MA, Philpotts, LL, Zafonte, R, Biederman, J (2018). Stimulant use in the management of mild traumatic brain injury: a qualitative literature review. J Atten Disord [Epub ahead of print] doi:10.1177/1087054718759752.Google Scholar
Ioannidis, K, Chamberlain, SR, Müller, U (2014a). Ostracizing caffeine from the pharmacological arsenal for ADHD: was this a correct decision? A literature review. J Psychopharmacol, 28, 830–836.Google Scholar
Ioannidis, K, Serfontein, J, Müller, U (2014b). Bulimia nervosa patient diagnosed with previously unsuspected adult ADHD: clinical case report, literature review, and diagnostic challenges. Int J Eat Disord, 47(4), 431–436.Google Scholar
Iwanami, A, Saito, K, Fujiwara, M, Okutsu, D, Ichikawa, H (2019). Randomized, double-blind, placebo-controlled, phase 3 study of guanfacine extended release in adults with attention-deficit/hyperactivity disorder. Presented at 7th World Congress on ADHD, Lisbon, Portugal.Google Scholar
Jackson, CO (1971). The amphetamine inhaler: a case study of medical abuse. J Hist Med, 26, 187–196.Google Scholar
Kessler, RC, Adler, L, Barkley, R, et al. (2006). The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry, 163(4), 716–723.Google Scholar
Khan, A, Fahl Mar, K, Brown, WA (2017). Does the increasing placebo response impact outcomes of adult and pediatric ADHD clinical trials? Data from the US Food and Drug Administration 2000–2009. J Psychiatr Res, 94, 202–207.Google Scholar
Koblan, KS, Hopkins, SC, Sarma, K, et al. (2016). Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. Drug Alcohol Depend, 159, 26–34.CrossRefGoogle ScholarPubMed
Konstenius, M, Jayaram-Lindström, N, Guterstam, J, et al. (2014). Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction, 109(3), 440–449.Google Scholar
Kooij, JJS (2013). Adult ADHD: Diagnostic Assessment and Treatment, 3rd ed. London: Springer.Google Scholar
Kooij, JJ, Huss, M, Asherson, P, et al. (2012). Distinguishing comorbidity and successful management of adult ADHD. J Atten Disord, 16(5 Suppl), 3–19.Google Scholar
Kooij, JJ, Michielsen, M, Kruithof, H, Bijlenga, D (2016). ADHD in old age: a review of the literature and proposal for assessment and treatment. Expert Rev Neurother, 16(12), 1371–1381.Google Scholar
Kooij, JJS, Bijlenga, D, Salerno, L, et al. (2019). Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry, 56, 14–34.Google Scholar
Kooij, SJ, Bejerot, S, Blackwell, A, et al. (2010). European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry, 10, 67.Google Scholar
Kratochvil, CJ, Newcorm, JH, Arnold, LE, et al. (2005). Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry, 44(9), 915–924.Google Scholar
Levin, FR, Mariani, JJ, Specker, S, et al. (2015). Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit/hyperactivity disorder and cocaine use disorder. JAMA Psychiatry, 72(6), 593–602.Google Scholar
Levin, FR, Choi, CJ, Pavlicova, M, et al. (2018). How treatment improvement in ADHD and cocaine dependence are related to one another: a secondary analysis. Drug Alcohol Depend, 188, 135–140.Google Scholar
Lichtenstein, P, Halldner, L, Zetterqvist, J, et al. (2012). Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med, 367, 2006–2014.Google Scholar
Lorvic, J, Bourgois, P, Wenger, LD, et al. (2012). Sexual pleasure and sexual risk among women who use methamphetamine: a mixed methods study. Int J Drug Policy, 23(5), 385–392.Google Scholar
Lu, Y, Sjölander, A, Cederlöf, M, et al. (2017). Association between medication use and performance on higher education entrance tests in individuals with attention-deficit/hyperactivity disorder. JAMA Psychiatry, 74(8), 815–822.Google Scholar
Magon, RK, Latheesh, B, Müller, U (2015). Specialist community adult ADHD clinics in East Anglia: service evaluation and audit of NICE guideline recommendations. BJPsych Bull, 39, 36–140.Google Scholar
Maier, LJ, Liechti, ME, Herzig, F, Schaub, MP (2013). To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students. PLoS One, 8(11), e77967.Google Scholar
Man, KKC, Ip, P, Chan, EW, et al. (2017). Effectiveness of pharmacological treatment for attention-deficit/hyperactivity disorder on physical injuries: a systematic review and meta-analysis of observational studies. CNS Drugs, 31, 1043–1055.Google Scholar
Martins, S, Tramontina, S, Polanczyk, G, et al. (2004). Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. J Child Adolesc Psychopharmacol, 14(2), 195–206.Google Scholar
Matthies, S, Philipsen, A (2016). Comorbidity of personality disorders and adult attention deficit hyperactivity disorder (ADHD): review of recent findings. Curr Psychiatry Rep, 18(4), 33.Google Scholar
McArdle, A (2016). Attention deficit hyperactivity disorder. In Currie, A, Owen, B, eds., Sports Psychiatry. Oxford: Oxford University Press, pp. 87–95.Google Scholar
McIntyre, RS, Lee, Y, Zhou, AJ, et al. (2017). The efficacy of psychostimulants in major depressive episodes: a systematic review and meta-analysis. J Clin Psychopharmacol, 37, 412–418.Google Scholar
Melendez-Torres, GJ, Bonell, C, Hickson, F, et al. (2016). Predictors of crystal methamphetamine use in a community-based sample of UK men who have sex with men. Int J Drug Policy, 36, 43–46.Google Scholar
Moran, LV, Ongur, D, Hsu, J, et al. (2019). Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med, 380, 1128–1138.Google Scholar
Müller, U (2008). Pharmacological treatment. In Cappa, SF, Abutalebi, J, Démonet, J-F, Fletcher, P, Garrard, P, eds., Cognitive Neurology: A Clinical Textbook. Oxford: Oxford University Press, pp. 475–498.Google Scholar
Müller-Sedgwick, U, Meisel, G, Nasri, M, Sedgwick-Müller, JA (2018). How fast should we titrate methylphenidate in adults with ADHD? A meta-analysis of dose titration regimes in RCTs. presented at 5th Eunethydis International Conference on ADHD, Edinburgh, Scotland.Google Scholar
National Institute for Health and Care Excellence (NICE) (2008). Attention deficit hyperactivity disorder: diagnosis and management. Clinical guideline [CG72]. London: National Institute for Health and Care Excellence.Google Scholar
National Institute for Health and Care Excellence (NICE) (2018). Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]. London: National Institute for Health and Care Excellence.Google Scholar
Newcorn, JH, Stein, MA, Childress, AC, et al. (2013). Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry, 52, 921–930.Google Scholar
NHS England (2016). The Five Year Forward View for Mental Health, Mental Health Taskforce. Available at: www.england.nhs.uk/mentalhealth/taskforce (last accessed 24.10.18).Google Scholar
Nigg, JT, Johnstone, JM, Musser, ED, et al. (2016). Attention-deficit/hyperactivity disorder (ADHD) and being overweight/obesity: new data and meta-analysis. Clin Psychol Rev, 43, 67–79.Google Scholar
Nussbaum, NL (2012). ADHD and female specific concerns: a review of the literature and clinical implications, J Atten Disord, 16, 87–100.CrossRefGoogle ScholarPubMed
Nutt, DJ, Fone, K, Asherson, P, et al.; British Association for Psychopharmacology (2007). Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 21(1), 10–41.Google Scholar
Ogundele, MO, Ayyash, HF (2018). Review of the evidence for the management of co-morbid tic disorders in children and adolescents with attention deficit hyperactivity disorder. World J Clin Pediatr, 7, 36–42.Google Scholar
Ott, R, Biller-Andorno, N (2014). Neuroenhancement among Swiss students: a comparison of users and non-users. Pharmacopsychiatry, 47, 22–28.Google Scholar
Padala, PR, Padala, KP, Lensing, SY, et al. (2018). Methylphenidate for apathy in community-dwelling older veterans with mild Alzheimer’s disease: a double-blind, randomized, placebo-controlled trial. Am J Psychiatry, 175, 159–168.Google Scholar
Park, J, Choi, HW, Yum, MS, et al. (2018). Relationship between aggravation of seizures and methylphenidate treatment in subjects with attention-deficit/hyperactivity disorder and epilepsy. J Child Adolesc Psychopharmacol, 28, 537–546.Google Scholar
Perera, B (2018). Attention deficit hyperactivity disorder in people with intellectual disability. Ir J Psychol Med, 35, 213–219.Google Scholar
Philipsen, A, Richter, H, Peters, J, et al. (2007). Structured group psychotherapy in adults with attention deficit hyperactivity disorder: results of an open multicentre study. J Nerv Ment Disord, 195(12), 1013–1019.Google Scholar
Philipsen, A, Limberger, MF, Lieb, K, et al. (2008). Attention-deficit hyperactivity disorder as a potentially aggravating factor in borderline personality disorder. Br J Psychiatry, 192(2), 118–123.Google Scholar
Philipsen, A, Jans, T, Graf, E, et al.; Comparison of Methylphenidate and Psychotherapy in Adult ADHD Study (COMPAS) Consortium (2015). Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry, 72, 1199–1210.Google Scholar
POMH-UK (2015). Topic 13b re-audit report. Prescribing for ADHD in children, adolescents and adults. Prescribing Observatory for Mental Health (POMH), CCQI218 (data on file).Google Scholar
Quinn, PO (2005). Treating adolescent girls and women with ADHD: gender-specific issue. J Clin Psychol, 61(5), 579–587.Google Scholar
Rabiner, DL, Anastopoulos, AD, Costello, EJ, et al. (2009). The misuse and diversion of prescribed ADHD medications by college students. J Atten Disord, 13, 144–153.Google Scholar
Renoux, C, Shin, JY, Dell’Aniello, S, Fergusson, E, Suissa, S (2016). Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995–2015. Br J Clin Pharmacol, 82, 858–868.Google Scholar
Reyniers, T, Hoornenborg, E, Vuylsteke, B, Wouters, K, Laga, M (2017). Pre-exposure prophylaxis (PrEP) for men who have sex with men in Europe: review of evidence for a much needed prevention tool. Sex Transm Infect, 93, 363–367.Google Scholar
Rösler, M, Fischer, R, Ammer, R, Ose, C, Retz, W (2009). A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci, 259(2), 120–129.Google Scholar
Roy, A, Hechtman, L, Arnold, LE, et al.; MTA Cooperative Group (2017). Childhood predictors of adult functional outcomes in the multimodal treatment study of attention-deficit/hyperactivity disorder (MTA). J Am Acad Child Adolesc Psychiatry, 56(8), 687–695.Google Scholar
Royal College of Psychiatrists (RCPsych) Psychopharmacology Committee (2017). Use of Licensed Medicines for Unlicensed Applications in Psychiatric Practice, 2nd ed. College Report CR210. London: Royal College of Psychiatrists. Available at: www.bap.org.uk/pdfs/CR210-December2017.pdf (last accessed 8.8.19).Google Scholar
Ruggiero, S, Clavenna, A, Reale, L, et al. (2014). Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis. Eur Neuropsychopharmacol, 24(10), 1578–1590.Google Scholar
Ruthirakuhan, MT, Herrmann, N, Abraham, EH, Chan, S, Lanctôt, KL (2018). Pharmacological interventions for apathy in Alzheimer’s disease. Cochrane Database Syst Rev, (5), CD012197.Google Scholar
Sahakian, BJ, Morein-Zamir, S (2015). Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people. Lancet Psychiatry, 2, 357–362.Google Scholar
Scheffer, RE (2007). Concurrent ADHD and bipolar disorder. Curr Psychiatry Rep, 9, 415–419.Google Scholar
Scheffer, RE, Kowatch, RA, Carmody, T, Rush, AJ (2005). Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry, 162(1), 58–64.Google Scholar
Sedgwick, JA (2018). University students with attention deficit hyperactivity disorder (ADHD): a literature review. Ir J Psychol Med, 35(3), 221–235.Google Scholar
Seixas, M, Weiss, M, Müller, U (2012). Systematic review of national and international guidelines on attention deficit hyperactivity disorder (ADHD). J Psychopharmacology, 26(6), 753–765.Google Scholar
Shanmugan, S, Epperson, CN (2014). Estrogen and the prefrontal cortex: towards a new understanding of estrogen’s effects on executive functions in the menopause transition. Hum Brain Mapp, 35(3), 847–865.Google Scholar
Singh, I, Bard, I, Jackson, J (2014). Robust resilience and substantial interest: a survey of pharmacological cognitive enhancement among university students in the UK and Ireland. PLoS One, 9(20), e105969.CrossRefGoogle ScholarPubMed
Slade, M (2017). Implementing shared decision making in routine mental health care. World Psychiatry, 16(2), 146–153.Google Scholar
Solberg, BS, Haavik, J, Halmøy, A (2019). Health care services for adults with ADHD: patient satisfaction and the role of psycho-education. J Atten Disord, 23, 99–108.CrossRefGoogle ScholarPubMed
Solmi, M, Fornaro, M, Toyoshima, K, et al. (2018). Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. CNS Spectr [Epub ahead of print] doi:10.1017/S1092852918001050.Google Scholar
Spruyt, K, Gozal, D (2011). Sleep disturbances in children with attention-deficit/hyperactivity disorder. Expert Rev Neurother, 11, 565–577.Google Scholar
Stein, M, Thurmond, P, Bailey, G (2014). Willingness to use HIV pre-exposure prophylaxis among opiate users. AIDS Behav, 18(9), 1694–1700.Google Scholar
Stoffers, JM, Völlm, BA, Rücker, G, et al. (2012). Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev, (8), CD005652.Google Scholar
Sugden, C, Housden, CR, Aggarwal, R, Sahakian, BJ, Darzi, A (2012). Effect of pharmacological enhancement on the cognitive and clinical psychomotor performance of sleep-deprived doctors: a randomized controlled trial. Ann Surg, 255(2), 222–227.Google Scholar
Surman, CBH, Fried, R, Rhodewalt, L, Boland, H (2017). Do pharmaceuticals improve driving in individuals with ADHD? A review of the literature and evidence for clinical practice. CNS Drugs, 31, 857–866.Google Scholar
Svedlund, NE, Norring, C, Ginsberg, Y, von Hausswolff-Juhlin, Y (2018). Are treatment results for eating disorders affected by ADHD symptoms? A one-year follow-up of adult females. Eur Eat Disord Rev, 26, 337–345.Google Scholar
Swanson, JM, Arnold, LE, Molina, BSG, et al.; MTA Cooperative Group (2017). Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry, 58(6), 663–678.Google Scholar
Tarrant, N, Roy, M, Deb, S, et al. (2018). The effectiveness of methylphenidate in the management of attention deficit hyperactivity disorder (ADHD) in people with intellectual disabilities: a systematic review. Res Dev Disabil, 83, 217–232.CrossRefGoogle ScholarPubMed
Taylor, E (2017). Attention deficit hyperactivity disorder: overdiagnosed or diagnoses missed? Arch Dis Child, 102, 376–379.Google Scholar
Taylor, E (2019). ADHD medication in the longer term. Z Kinder Jugendpsychiatr Psychother [Epub ahead of print] doi:10.1024/1422-4917/a000664.Google Scholar
Thorpy, MJ (2015). Update on therapy for narcolepsy. Curr Treat Options Neurol, 17(5), 347.Google Scholar
Tomlinson, D, Robinson, PD, Oberoi, S, et al. (2018). Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis. Curr Oncol, 25, e152–e167.Google Scholar
Torgersen, T, Gjervan, B, Lensing, MB, Rasmussen, K (2016). Optimal management of ADHD in older adults. Neuropsychiatr DisTreat, 12, 79–87.Google Scholar
Tritsch, NX, Sabatini, BL (2012). Dopaminergic modulation of synaptic transmission in cortex and striatum. Neuron, 76(1), 33–50.Google Scholar
UK Medicines Information (2017). Which medicines should be considered for brand-name prescribing in primary care? Available at: www.sps.nhs.uk/wp-content/uploads/2017/12/UKMi_QA_Brand-name_prescribing_Update_Nov2017.pdf (last accessed 9.8.19).Google Scholar
van Reekum, R, Links, PS (1994). N of 1 study: methylphenidate in a patient with borderline personality disorder and attention deficit hyperactivity disorder. Can J Psychiatry, 39(3), 186–187.Google Scholar
Verrotti, A, Moavero, R, Panzarino, G, et al. (2018). The challenge of pharmacotherapy in children and adolescents with epilepsy-ADHD comorbidity. Clin Drug Investig, 38(1), 1–8.Google Scholar
Viktorin, A, Rydén, E, Thase, ME, et al. (2017). The risk of treatment-emergent mania with methylphenidate in bipolar disorder. Am J Psychiatry, 174(4), 341–348.Google Scholar
Wilens, TE, Morrison, NR (2011). The intersection of attention-deficit/hyperactivity disorder and substance abuse. Curr Opin Psychiatry, 24(4), 280–285.Google Scholar
Wilens, TE, Adler, LA, Adams, J, et al. (2008). Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry, 47, 21–31.Google Scholar
Wilens, TE, Adler, LA, Weiss, MD, et al.; Atomoxetine ADHD/SUD Study Group (2008). Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend, 96(1–2), 145–154.Google Scholar
Williamson, D, Johnston, C (2015). Gender differences in adults with attention-deficit/hyperactivity disorder: a narrative review. Clin Psychol Rev, 40, 15–27.Google Scholar
Wilson, SJ, Nutt, DJ, Alford, C, et al. (2010). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol, 24, 1577–1601.Google Scholar
Wolraich, M, Brown, L, Brown, RT, et al. (2011). ADHD: clinical practice guideline for the diagnosis, evaluation and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 128(5), 1007–1022.Google Scholar
Wood, DR, Reimherr, FW, Wender, PH, Johnson, GE (1976). Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry, 33(12), 1453–1460.Google Scholar
World Health Organization (2011). Technical Brief 1: Patterns and consequences of the use of amphetamine-type stimulants (ATS). Available at: www.wpro.who.int/hiv/documents/docs/Brief1forweb_850A.pdf (last accessed 1.8.18).Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×